Tg Therapeutics (TGTX) Inventory Average (2023 - 2026)

Tg Therapeutics' Inventory Average history runs 4 years deep, the most recent figure standing at $127.3 million for Q1 2026.

• On a quarterly basis, Inventory Average fell 5.07% year-over-year to $127.3 million in Q1 2026; TTM through Mar 2026 was $127.3 million, a 5.07% decrease from a year earlier, with the FY2025 full-year figure at $118.0 million, up 57.07% from the prior year.
• Inventory Average declined to $127.3 million in Q1 2026 per TGTX's latest filing, from $136.3 million in the prior quarter.
• Across five years, Inventory Average topped out at $156.5 million in Q2 2025 and bottomed at $28.7 million in Q2 2023.
• The 4-year median for Inventory Average is $90.3 million (2024), against an average of $93.4 million.
• Across the five-year window, Inventory Average jumped 176.67% in 2024 and decreased 5.07% in 2026, its largest moves.
• Year by year, Inventory Average stood at $36.7 million in 2023, then soared by 165.93% to $97.6 million in 2024, then jumped by 39.67% to $136.3 million in 2025, then retreated by 6.58% to $127.3 million in 2026.
• Per Business Quant, the three latest TGTX Inventory Average figures stand at $127.3 million (Q1 2026), $136.3 million (Q4 2025), and $151.1 million (Q3 2025).